TITLE

Review: Antifungals absorbed or partially absorbed from the GI tract prevent oral candidiasis in cancer patients receiving treatment

AUTHOR(S)
Nicolle, Lindsay
PUB. DATE
March 2003
SOURCE
ACP Journal Club;Mar/Apr2003, Vol. 138 Issue 2, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the effectiveness of antifungal drugs among cancer patients who are receiving chemotheraphy or radiotheraphy. Changes in cancer treatment; Outcomes of the study; Prevention of oral candidiasis.
ACCESSION #
9333429

 

Related Articles

  • Hepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome. Thaler, Michael; Pastakia, Behram; Shawker, Thomas H.; O'Leary, Timothy; Pizzo, Philip A. // Annals of Internal Medicine;Jan88, Vol. 108 Issue 1, p88 

    Presents a study which examined the evolving nature of hepatosplenic candidiasis, focusing on diagnosis and treatment. Characteristics of focal hepatosplenic; Use of intensive chemotherapy; Reason for recommending the use of empirical anti-fungal therapy for high-risk patients; Description of...

  • Isavuconazole: as effective as, but better tolerated than standard antifungal therapy. Lyon, Sue // British Journal of Hospital Medicine (17508460);Oct2014, Vol. 75 Issue 10, p551 

    The article discusses the findings of a study which reveals that novel antifungal drug isavuconazole can be better than standard antifungal therapy for the treatment of invasive mold disease in cancer patients.

  • New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. Costa, Catarina; Ponte, Andreia; Pais, Pedro; Santos, Rui; Cavalheiro, Mafalda; Yaguchi, Takashi; Chibana, Hiroji; Teixeira, Miguel Cacho // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1 

    5-Flucytosine is currently used as an antifungal drug in combination therapy, but fungal pathogens are rapidly able to develop resistance against this drug, compromising its therapeutic action. The understanding of the underlying resistance mechanisms is crucial to deal with this problem. In...

  • A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Knitsch, Wolfgang; Vincent, Jean-Louis; Utzolino, Stefan; François, Bruno; Dinya, Tamás; Dimopoulos, George; Özgüneş, İlhan; Valía, Juan Carlos; Eggimann, Philippe; León, Cristóbal; Montravers, Philippe; Phillips, Stephen; Tweddle, Lorraine; Karas, Andreas; Brown, Malcolm; Cornely, Oliver A. // Clinical Infectious Diseases;12/1/2015, Vol. 61 Issue 11, p1671 

    Background: Patients undergoing emergency gastrointestinal surgery for intra-abdominal infection are at risk of invasive candidiasis (IC) and candidates for preemptive antifungal therapy. Methods: This exploratory, randomized, double-blind, placebo-controlled trial assessed a preemptive...

  • Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. Falcone, Marco; Accarpio, Fabio; Venditti, Mario; Vena, Antonio; Sibio, Simone; Sammartino, Paolo; Giorgio, Angelo Di // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2266 

    The article discusses septic bilateral pulmonary candidiasis treated with anidulafungin therapy. Particular focuses is given to the two cases of patients with peritoneal carcinomatosis, one from lower rectal cancer, and the other from advanced gastric cancer. Both were administered with...

  • Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review. Lass-Florl, Cornelia // Drugs;2011, Vol. 71 Issue 18, p2405 

    Invasive fungal disease continues to be a problem associated with significant morbidity and high mortality in immunocompromised and, to a lesser extent, immunocompetent individuals. Triazole antifungals have emerged as front-line drugs for the treatment and prophylaxis of many systemic mycoses....

  • Fungal Infections in Leukemia Patients: How Do We Prevent and Treat Them? Leventakos, Konstantinos; Lewis, Russell E.; Kontoyiannis, Dimitrios P. // Clinical Infectious Diseases;2/1/2010, Vol. 50 Issue 3, p405 

    Invasive fungal infections (IFIs) remain an important cause of morbidity and mortality in patients with acute or chronic leukemia. Advances in the pharmacotherapy of fungal infections and a shift in the epidemiological characteristics of fungal pathogens toward fluconazole-resistant Candida...

  • Pharmacotherapy of Candida Infections with Echinocandins. Espinel-Ingroff, ,3Ana; Canton, Emilia; Martin-Mazuelos, Estrella; Pemán, Javier // Clinical Medicine: Therapeutics;2009, Issue 1, p889 

    The classic recommended antifungal agents for the treatment of invasive Candida infections were amphotericin B, a lipid formulation of amphotericin B and fluconazole in both neutropenic or nonneutropenic patients as either primary or alternative therapies. Voriconazole has been recommended when...

  • Adjuvant Corticosteroid Therapy in Hepatosplenic Candidiasis-Related Iris. Bayram, Cengiz; Fettah, Ali; Yarali, Nese; Kara, Abdurrahman; Azik, Fatih Mehmet; Tavil, Betul; Tunc, Bahattin // Mediterranean Journal of Hematology & Infectious Diseases;2012, Vol. 4 Issue 1, p1 

    Candida infections are the most frequent infections in neutropenic patients. Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics